

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1-176 (Cancelled)

177. (Previously Presented) A method of treating a human patient having a disease characterized by an amyloid deposit in the brain of the patient comprising the step of administering to the patient a) a therapeutically effective dose of the antibody 10D5 deposited as ATCC accession number PTA-5129; and b) a pharmaceutically acceptable carrier, thereby therapeutically treat the disease in the human patient.

178-195. (Cancelled)

196. (Previously Presented) The method of claim 177, wherein the disease is Alzheimer's disease and the amyloid deposit is formed by aggregation of A β .

197. (Cancelled)

198. (Previously Presented) The method of claim 177, wherein administration is intravenous, intramuscular or subcutaneous.